USRM Stock Overview
A biotechnology company, engages in the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
U.S. Stem Cell, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.0001 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 11 Month Change | -99.00% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -99.99% |
| 5 Year Change | -99.98% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| USRM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 4.3% | 1.6% |
| 1Y | n/a | 18.8% | 32.3% |
Return vs Industry: Insufficient data to determine how USRM performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how USRM performed against the US Market.
Price Volatility
| USRM volatility | |
|---|---|
| USRM Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: USRM's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine USRM's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | n/a | Mike Tomas | www.us-stemcell.com |
U.S. Stem Cell, Inc., a biotechnology company, engages in the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States. The company’s lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient’s heart with autologous muscle cells or cells from a patient’s body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia. Its pipeline products include MyoCell SDF-1, an autologous muscle-derived cellular therapy for enhancing cardiac function in chronic heart failure patients.
U.S. Stem Cell, Inc. Fundamentals Summary
| USRM fundamental statistics | |
|---|---|
| Market cap | US$661.00 |
| Earnings (TTM) | -US$2.86m |
| Revenue (TTM) | US$82.05k |
0.0x
P/S Ratio0.0x
P/E RatioIs USRM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| USRM income statement (TTM) | |
|---|---|
| Revenue | US$82.05k |
| Cost of Revenue | US$23.77k |
| Gross Profit | US$58.28k |
| Other Expenses | US$2.92m |
| Earnings | -US$2.86m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did USRM perform over the long term?
See historical performance and comparison